Less Survivable Cancers

Monica Harding Excerpts

Tuesday 6th January 2026 Westminster Hall

[Monica Harding (Esher and Walton) (LD)]

It is a pleasure to serve under your chairship, Mr Efford. I congratulate my hon. Friend the Member for Wokingham (Clive Jones) on securing this vital debate on less survivable cancers.

As it is for many people across Parliament and the country, less survivable cancer is a personal fight for me. My brother-in-law, Group Captain Pip Harding, was diagnosed two years ago with glioblastoma, a devastating and aggressive brain tumour. His story illustrates both hope and what is still profoundly broken. Pip received pioneering oncothermia treatment from Dr Paul Mulholland, who has been mentioned by the hon. Member for Mitcham and Morden (Dame Siobhain McDonagh). The treatment shrank his tumour significantly; he had a prognosis of only six months to live with his five children and wife, but two years on he is still alive and well. But that treatment remains inaccessible on the NHS: he obtained it through his family and friends crowdfunding the treatment, which illustrates how those with the means and community support can access innovation while others cannot.

Glioblastoma remains one of the hardest cancers to treat, with little improvement in survival rates compared with many other cancers. We know that research funding for brain tumours has historically lagged behind need, and it receives a tiny fraction of overall cancer research pounds, which is a scandal when the disease disproportionately affects younger adults. I support the sterling work of the hon. Member for Mitcham and Morden on trials, and I echo her ask.

I have heard from many families in my constituency of Esher and Walton whose lives have been turned upside down by rare cancers. One constituent shared the anguish of watching their partner struggle with a less common blood cancer that had no clear trial available in the UK, even though promising research was under way abroad. These stories are not isolated. They reflect systemic issues, including diagnostic delays. Here, I will bring in my lovely sister Mary, who died just before Christmas. She waited for a diagnosis, but was misdiagnosed and died from bowel cancer. Trial access is limited and specialist expertise across regions is patchy. Just 82.5% of cancer patients in Esher and Walton began treatment within 62 days of an urgent referral, below the operational standard of 85%. Every per cent represents the heartbreak that my family felt this Christmas.

I also want to raise lobular breast cancer. It is the second most common form of breast cancer, yet it remains under-researched and under-supported. In collaboration with the lobular moonshot project, my constituent Kate Ford has been campaigning for the Government to commit £20 million for a dedicated research programme. However, after Kate had a meeting with the Secretary of State in July, the Government chose not to commit to that. Instead, they supported a broader research base, but that largely misses the point, because the status quo of research programmes means that rare cancers such as lobular breast cancer are effectively left behind.

Finally, I want to return to brain cancer and Owain’s law, which addresses issues where patients lose access to cutting edge therapies due to improper tissue preservation—

[Clive Efford (in the Chair)]

Order. I call Dr Peter Prinsley.